Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review

Petit, Joel; Carroll, Georgia; Gould, Tiffany; Pockney, Peter; Dun, Matthew D.; Scott, Rodney J.

doi:10.1016/j.jss.2018.11.029

Cited by 64 publications

(41 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several blood-based biomarkers, including carcioembriogenic antigen (CEA) and carbohydrate antigen (CA) 19-9 are well established in clinical practice, howbeit, low specificity and sensitivity are key limitations of these tests (10). Recent advances in -omics technologies enabled discovery of new potential biomarkers, including different proteins (11), circulating tumor DNA (12,13) or microRNA (14) and circulating tumor cells (15) as well as numerous metabolites (16,17) and transcriptional biomarkers (18). Despite many of these biomarkers demonstrated high diagnostic potential in retrospective proof-of-concept studies, further research is required to determine their clinical validity and utility (11).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of Combinatorial Markers in Colorectal Carcinoma

Voronova¹,

Glybochko

Svistunov

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Objectives: Blood-based tests have been shown to be an effective strategy for colorectal cancer (CRC) detection in screening programs. This study was aimed to test the performance of 20 blood markers including tumor antigens, inflammatory markers, and apolipoproteins as well as their combinations. Methods: In total 203 healthy volunteers and 102 patients with CRC were enrolled into the study. Differences between healthy and cancer subjects were evaluated using Wilcoxon rank-sum test. Several multivariate classification algorithms were employed using information about different combinations of biomarkers altered in CRC patients as well as age and gender of the subjects; random sub-sampling cross-validation was done to overcome overfitting problem. Diagnostic performance of single biomarkers and multivariate classification models was evaluated by receiver operating characteristic (ROC) analysis. Results: Of 20 biomarkers, 16 were significantly different between the groups (p-value ≤ 0.001); ApoA1, ApoA2 and ApoA4 levels were decreased, whereas levels of tumor antigens (e.g. carcinoembriogenic antigen) and inflammatory markers (e.g., C-reactive protein) were increased in CRC patients vs. healthy subjects. Combinatorial markers including information about all 16 significant analytes, age and gender of patients, demonstrated better performance over single biomarkers with average accuracy on test datasets ≥95% and area under ROC curve (AUROC) ≥98%. Conclusions: Combinatorial approach was shown to be a valid strategy to improve performance of blood-based CRC diagnostics. Further evaluation of the proposed models in screening programs will be performed to gain a better understanding of their diagnostic value.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of Combinatorial Markers in Colorectal Carcinoma

Voronova¹,

Glybochko

Svistunov

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Aimed to predict better the therapeutic response against EGFR, some researchers analyzed point mutations in the KRAS gene, because its mutated versions are associated with the inefficiency of the cetuximab/panitumumab-based therapy [36][37][38][39]101,102]. KRAS mutations have been noted in almost 40% of all CRC, from which about 95% was found in codons 12 and 13 [101,103]. KRAS G12D (sometimes wrongly called KRAS G12DM) is the most reported KRAS point mutation in CRC [104,105].…”

Section: Electrochemical Biosensing Of Nucleic Acid Biomarkers Of Crcmentioning

confidence: 99%

Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers

et al. 2020

View full text Add to dashboard Cite

The accurate determination of specific tumor markers associated with cancer with non-invasive or minimally invasive procedures is the most promising approach to improve the long-term survival of cancer patients and fight against the high incidence and mortality of this disease. Quantification of biomarkers at different stages of the disease can lead to an appropriate and instantaneous therapeutic action. In this context, the determination of biomarkers by electrochemical biosensors is at the forefront of cancer diagnosis research because of their unique features such as their versatility, fast response, accurate quantification, and amenability for multiplexing and miniaturization. In this review, after briefly discussing the relevant aspects and current challenges in the determination of colorectal tumor markers, it will critically summarize the development of electrochemical biosensors to date to this aim, highlighting the enormous potential of these devices to be incorporated into the clinical practice. Finally, it will focus on the remaining challenges and opportunities to bring electrochemical biosensors to the point-of-care testing.

show abstract

“…The ever-increasing interest in epigenetic analysis paired with the convenience of liquid biopsy sampling naturally leads to questions on quality, efficiency, and standardization of sample preparation techniques [1]. Aberrant DNA methylation detected in liquid biopsies is a clinically useful biomarker for detection of cancer in the colon, rectum, liver or lung [2,3,4].…”

Section: Introductionmentioning

confidence: 99%

An automated high throughput solution for DNA extraction and bisulfite-conversion from high volume liquid biopsy specimens – sample preparation for epigenetic analysis

Rausch

Hasinger

König

et al. 2019

Preprint

View full text Add to dashboard Cite

Objective: DNA methylation analysis via real-time PCR or other analytical techniques requires purified bisulfite converted DNA. We report on an automated high throughput solution for DNA extraction, bisulfite-conversion, and purification of 96 samples with an input volume of up to 3.5mL of plasma or urine, using reagents from the commercially available Epi BisKit. Results: Magnetic bead-based DNA extraction, bisulfite conversion at high temperature, and efficient DNA purification was conducted on a customized commercially available liquid-handling platform. A highly interlaced 4x24 sample protocol was implemented for DNA extraction, elution in a 96-well plate, efficient bisulfite-conversion and extensive purification. The resulting bisulfite-converted DNA was stored in a 96-well format, ready for PCR set-up or other down-stream applications. The automated method is a walk-away solution for processing 96 samples in 7h30min. Performance of the method was validated by comparison with the standard manual method of the Epi BiSKit using technical and biological samples. Overall DNA yield was assessed with a standardized ß-actin assay. The automated workflow demonstrated equivalent performance to the manual method for technical, plasma and urine samples. It may provide a new standard for effective high-throughput preparation of bisulfiteconverted DNA from a variety of high volume liquid biopsy specimens.

show abstract

Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review

Cited by 64 publications

References 55 publications

Diagnostic Value of Combinatorial Markers in Colorectal Carcinoma

Diagnostic Value of Combinatorial Markers in Colorectal Carcinoma

Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers

An automated high throughput solution for DNA extraction and bisulfite-conversion from high volume liquid biopsy specimens – sample preparation for epigenetic analysis

Contact Info

Product

Resources

About